DK175704B1 - Inhibering af arteriel thrombotisk okklusion eller thromboenboli - Google Patents

Inhibering af arteriel thrombotisk okklusion eller thromboenboli Download PDF

Info

Publication number
DK175704B1
DK175704B1 DK198806400A DK640088A DK175704B1 DK 175704 B1 DK175704 B1 DK 175704B1 DK 198806400 A DK198806400 A DK 198806400A DK 640088 A DK640088 A DK 640088A DK 175704 B1 DK175704 B1 DK 175704B1
Authority
DK
Denmark
Prior art keywords
activated protein
protein
apc
pharmaceutical composition
dose
Prior art date
Application number
DK198806400A
Other languages
Danish (da)
English (en)
Other versions
DK640088A (da
DK640088D0 (da
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of DK640088D0 publication Critical patent/DK640088D0/da
Publication of DK640088A publication Critical patent/DK640088A/da
Application granted granted Critical
Publication of DK175704B1 publication Critical patent/DK175704B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK198806400A 1987-11-17 1988-11-16 Inhibering af arteriel thrombotisk okklusion eller thromboenboli DK175704B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12170287 1987-11-17
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (3)

Publication Number Publication Date
DK640088D0 DK640088D0 (da) 1988-11-16
DK640088A DK640088A (da) 1989-05-18
DK175704B1 true DK175704B1 (da) 2005-01-24

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198806400A DK175704B1 (da) 1987-11-17 1988-11-16 Inhibering af arteriel thrombotisk okklusion eller thromboenboli

Country Status (11)

Country Link
US (2) US5084274A (fr)
EP (1) EP0318201B1 (fr)
JP (1) JP2766986B2 (fr)
AT (1) ATE135234T1 (fr)
CA (1) CA1330036C (fr)
DE (1) DE3855096T2 (fr)
DK (1) DK175704B1 (fr)
ES (1) ES2086301T3 (fr)
FI (1) FI104790B (fr)
GR (1) GR3020036T3 (fr)
NO (1) NO301747B1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
WO1991009960A1 (fr) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Proteine c hybride
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
ES2082465T3 (es) * 1991-04-16 1996-03-16 Boehringer Mannheim Gmbh Unidad farmaceutica de envasado que contiene activadores de plasminogeno para la administracion multiple de bolos.
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1993009807A1 (fr) * 1991-11-18 1993-05-27 The Scripps Research Institute Procedes d'inhibition de la thrombose par elevation des taux de proteine c activee endogene dans la circulation
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US6143719A (en) * 1995-06-09 2000-11-07 The Regents Of The University Of Michigan Bradykinin analogs as selective thrombin inhibitors
JP4680329B2 (ja) * 1997-03-24 2011-05-11 カーディオム ファーマ コーポレイション 血管障害の治療方法
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
CA2293429A1 (fr) * 1997-06-05 1998-12-10 Eli Lilly And Company Procede de traitement de troubles thrombotiques
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US7074402B2 (en) 2000-02-04 2006-07-11 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC)
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (fr) 2000-05-24 2001-11-29 Eli Lilly And Company Preparations et techniques permettant de traiter des hypercoagulations
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (fr) 2002-12-05 2004-07-08 Socratech L.L.C. Activite neuroprotectrice de la proteine c activee independante de son activite anticoagulante
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (fr) * 2003-07-08 2014-11-26 The Scripps Research Institute Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
EP1773371A4 (fr) * 2004-07-23 2009-12-30 Univ Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
WO2008073603A2 (fr) * 2006-10-31 2008-06-19 The Scripps Research Institute Schéma posologique de protéine c activée et de ses variants présentant une activité anticoagulante réduite
EP2146948A4 (fr) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc Utilisation de transcaroténoïdes bipolaires en tant que traitement préalable et dans le traitement de pathologies vasculaires périphériques
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (fr) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Formes pharmaceutiques orales à base de caroténoïdes trans bipolaires
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
EP3432929A4 (fr) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC Utilisation de caroténoïdes trans bipolaires avec une chimiothérapie et une radiothérapie en vue du traitement d'un cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
FI104790B (fi) 2000-04-14
DK640088A (da) 1989-05-18
EP0318201B1 (fr) 1996-03-13
NO301747B1 (no) 1997-12-08
DK640088D0 (da) 1988-11-16
ATE135234T1 (de) 1996-03-15
GR3020036T3 (en) 1996-08-31
FI885331A0 (fi) 1988-11-17
FI885331A (fi) 1989-05-18
JPH01238536A (ja) 1989-09-22
NO885109L (no) 1989-05-18
EP0318201A2 (fr) 1989-05-31
US5350578A (en) 1994-09-27
ES2086301T3 (es) 1996-07-01
DE3855096T2 (de) 1996-07-25
DE3855096D1 (de) 1996-04-18
EP0318201A3 (en) 1990-02-07
NO885109D0 (no) 1988-11-16
US5084274A (en) 1992-01-28
CA1330036C (fr) 1994-06-07
JP2766986B2 (ja) 1998-06-18

Similar Documents

Publication Publication Date Title
DK175704B1 (da) Inhibering af arteriel thrombotisk okklusion eller thromboenboli
Gold et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Golino et al. Antithrombotic effects of recombinant human, active site–blocked factor VIIa in a rabbit model of recurrent arterial thrombosis
Nilsson et al. Effect of venous occlusion on coagulation and fibrinolytic components in normal subjects
Patel et al. Quality improvement guidelines for percutaneous management of acute lower-extremity ischemia
HU219682B (hu) Módosított VII faktor
JP2008289498A (ja) 精製されたマルチメラ−ゼ
Kelly et al. Antihemophilic factor inhibitors: Management with prothrombin complex concentrates
Vinazzer Clinical use of antithrombin III concentrates
Gitel et al. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications
Dosekun et al. Ancrod in systemic lupus erythematosus with thrombosis: clinical and fibrinolysis effects
FI103577B (fi) Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamisek si
JP5236952B2 (ja) 改善された特性を有するｆｘｉｉｉバリアント
Moran et al. The role of thrombolytic therapy in surgical practice
WO1993009807A1 (fr) Procedes d'inhibition de la thrombose par elevation des taux de proteine c activee endogene dans la circulation
Jeljaszewicz et al. Intravascular Coagulation and Fibrinolysis by Stapliylocoagiilase. Comparison with Thrombin
US9211317B2 (en) Method of using prourokinase in facilitated percutaneous coronary intervention in patients with acute myocardial infarction
EP1067879B1 (fr) Methode d'inhibition de la thrombose chez un patient dont le sang est soumis a une circulation extracorporelle
Bergstein et al. Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction
Quick Thromboplastin as a reagent
JP3878668B2 (ja) 血栓性疾患の治療
Dubber et al. Acquired Hypofibrinogenaemia—‘The Defibrination Syndrome’ A Study of 7 Patients
Roudaut et al. Thrombolytic treatment of acute thrombotic obstruction with disk valve prostheses: experience with 26 cases
Aoki et al. Severe heat stroke associated with high plasma levels of plasminogen activator inhibitor 1
US20020031518A1 (en) Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field

Legal Events

Date Code Title Description
PUP Patent expired